Neurovalens raises over £5m as it seeks regulatory approval

July 20, 2020

Irish healthtech company Neurovalens has raised £5.1 million (€5.6 million) as it looks to secure regulatory approval for headset it has developed that can be used to help treat a range of conditions, including insomnia.

The company, which is dual-headquartered in Belfast and San Diego, is to use the new financing to expand on the success of initial clinical trials and further develop its technology for use with other medical conditions.

The latest fundraise brings total investment in the company to date to over £11 million It was led by long-term backer IQ Capital. Other participants included Wharton Asset Management Company, The Angel CoFund, Techstart Ventures, Co-Fund II managed by Clarendon Fund Managers and the UK government’s Future Fund.

Read the full story on the Irish Times website here

What formal constitution must the Syndicate have?
Read FAQs

Investment Team

Meet the team

We’re pretty sparing with our email comms, but when there are interesting and relevant things happening it’s great to share. If you’d like to receive updates and hear more about what is happening with ACF Investors and the portfolio then please sign up here.

Website by James Dowen Web Designer Web Developer Web design london